SYRA HEALTH CORP.

SYRA

CIK 0001922335 · Quarterly mode · latest period FY2025 (Q4) (ending 2025-12-31) · sourced from SEC EDGAR

At a glance · FY2025 (Q4)

Revenue
$2M
↓-13.6% -$273Kvs FY2024 (Q4)
Operating Income
$352K
↑+105.4% +$181Kvs FY2024 (Q4)
Net Income
$348K
↑+109.6% +$182Kvs FY2024 (Q4)
Gross Profit
$591K
↑+65.9% +$235Kvs FY2024 (Q4)

Quality Score

Quality score

6-dimension fundamental snapshot · latest annual filed values · S&P 500 calibration

Average
50/100
  • Profitability
    0ROIC -28.7% (10% = solid, 20%+ = moat)
  • Liquidity
    100Current Ratio 4.06 (above 1.5 = solid)
  • Leverage
    0Insufficient data
  • Efficiency
    100Asset Turnover 2.24x (1.0+ = capital-efficient)
  • Growth
    0Revenue YoY -13.6% (10% = solid, 25%+ = elite)
  • Margin Trend
    100Op Margin -13.8% · trend +43.2pts (4Q avg vs prior 4Q)

Calibrated to S&P 500 medians. Each sub-score is computed from a single CFA-grade ratio (Profitability = ROIC, Liquidity = Current Ratio, Leverage = D/E, Efficiency = Asset Turnover, Growth = Revenue YoY, Margin Trend = 4Q operating-margin avg vs prior 4Q). Overall = simple mean.

Capital allocation · trailing 4 quarters

how the company spent its cash
Capex (TTM)
investment in PP&E
Stock-based comp (TTM)
$99K
non-cash dilution

Balance sheet · 2025-12-31

latest filed snapshot
Total assets
$3M
everything owned
Total liabilities
$675K
everything owed
Stockholders' equity
$2M
shareholder claim

Recent performance · 14 quarters

Revenue↓-13.6% -$273K
$2M
Net Income↑+45.9% +$192K
$-226K
Free Cash Flow↑+119.6% +$965K
$158K
Operating Margin↑+5.3pts
-13.8%

Drill down